去纤维钠注射后多久产生副作用？

(Defibrotide sodium) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide (defibrotide sodium) can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells. So how long will it take for side effects to appear after taking defibrinoside (defiber sodium)? What are the common side effects?

Since each patient's condition is different, their tolerance to drugs is also different, and the time when side effects occur cannot be determined.

The most common side effects of defibrotide treatment (incidence ≥10% and independent causal relationship) are hypotension, diarrhea, vomiting, nausea and epistaxis. The incidence rate of grade 3-4 reactions related to defibrotide (defibrotide sodium) was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients stopped treatment due to side effects. In other words, the side effects of defibrotide (defibrotide sodium) are usually mild, and patients do not need to worry too much.

It is important to note that defibrinoside (desoside) may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase. The concomitant use of defibrotide (defibrotide sodium) with antithrombotic or fibrinolytic drugs is contraindicated due to an increased risk of bleeding. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding. If a patient bleeds while taking defibrotide (sodium defibrination), the use of defibrination (sodium defibrination) should be discontinued, the cause of the disease should be identified, and supportive medical care should be provided until the bleeding stops.

(Defibrotide Sodium) is not currently on the market in my country. If patients need to purchase medicine, they can consult their medical companions.

Recommended related hot articles: /newsDetail/83356.html